Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Copenhagen University Hospital at Herlev | OTHER |
| Novo Nordisk A/S | INDUSTRY |
| Danish Cancer Society | OTHER |
| TrygFonden, Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Colorectal cancer is one of the most common cancers in Denmark, annually 4,200 men and women are diagnosed and approx. 2000 patients die of their colorectal cancer. As with other cancers, the risk of colorectal cancer increases with age, and the median age at diagnosis is 71 years. Improved treatment has increased the number of survivors with an expected 5-year survival rate of 50-60%. Characteristic of this group of patients is that at the time of diagnosis they often live with comorbidities and have limited leisure time physical activity.
There is evidence that rehabilitation in the form of physical exercise for cancer patients after their initial treatment has a positive effect on a number of physical and psychological parameter such as health-related quality of life, physical capacity and physical function, fatigue, anxiety and depression. However, the most frequently studied diagnosis group is women with breast cancer. Until now only few studies have evaluated the effects of physical activity among colorectal cancer patients receiving chemotherapy
The purpose of this study is: to examine the effect of two different training initiatives - 12 weeks progressive, high-intensity training versus low intensity exercise intervention - on physical, emotional and social habitus, in sedentary patients with colorectal cancer during adjuvant chemotherapy.
The hypothesis of the study are: 1. That both interventions will show a positive association between increased physical capacity (measured by aerobic capacity VO2-peak / peak oxygen uptake) and improved physical function, reduced fatigue and anxiety in the included sedentary colorectal cancer patients undergoing adjuvant chemotherapy.
Participants: Patients undergoing adjuvant chemotherapy for colorectal cancer who have self-reported physical activity level below the national recommended levels (less than 150 min/week of moderate leisure time physical activity, and exercises at least 20 minutes of strenuous physical activity twice a week).
Benefits and risks of participating: Possible benefits of the interventions: to reduce treatment related symptoms and side-effects, increase vitality and well-being and promote lifestyle changes among sedentary colorectal cancer patients receiving adjuvant chemotherapy. At participation in the interventions minor sports injuries may occur.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pedometer intervention | Active Comparator | Individual progressive pedometer intervention of low to moderate intensity. Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity. |
|
| Pedometer + hospital based intervention | Active Comparator | Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pedometer intervention | Behavioral | 12 weeks physical activity intervention (supervised/non-supervised) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum oxygen uptake - ( VO2 peak) | Assessed with objective physiological test | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Health related Quality of Life | Assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, specifically for colon cancer patients | From baseline to 39 weeks |
| Symptoms and side-effects |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lis Adamsen, Professor | Rigshospitalet, Denmark | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Copenhagen | 2100 | Denmark |
Presently no plan to make IPD available to other researchers
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| INDUSTRY |
Not provided
Not provided
Not provided
Primary outcome (VO2 peak) Physiological tests assessors blinded
| Pedometer + hospital based intervention | Behavioral | 12 weeks physical activity intervention (supervised/non-supervised) |
|
| Omron Walking Style pro. 20 | Device |
|
|
Assessed by MD Andersen symptom questionnaire and The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, chemotherapy-induced peripheral neuropathy
| From baseline to 39 weeks |
| Anxiety and Depression | Assessed by The Hospital Anxiety and Depression Scale | From baseline to 39 weeks |
| Lifestyle factors | Assessed by smoking cessation, alcohol, diet | From baseline to 39 weeks |
| Physical activity level | Assessed by the International Physical Activity Questionnaire | From baseline to 39 weeks |
| Dual Energy X-ray Absorptiometry scan | Assessed by dual energy x-ray absorptiometry. | From baseline to 39 weeks |
| Blood cholesterols | Assessed by blood samples | From baseline to 39 weeks |
| Blood pressure / pulse | Assessed by Heart Rate Monitor during the hospital-based intervention | From 6 to 12 weeks |
| Pedometer Step Count | Assessed by Omron Walking Style pro. 20 with electronic data transmission | From baseline to 12 weeks |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |